molecules_istock-157742535_blackjack3d
blackjack3d / iStockphoto.com
5 July 2017Big Pharma

GSK enters drug discovery collaboration with AI-driven company

GSK has entered into a strategic drug discovery collaboration with an artificial intelligence-driven (AI) drug discovery company, Exscientia.

Under the agreement, Exscientia will apply its AI-enabled platform in combination with GSK’s expertise to discover novel and selective small molecules for ten diseases.

GSK will also pay Exscientia to undertake new discovery programmes.

According to a statement released on Sunday, July 2, Exscientia will also be eligible to get a milestone payment of £33 million ($43 million) if all objectives are achieved.

Andrew Hopkins, CEO of Exscientia, said: "The alliance provides further validation of our AI-driven platform and its potential to accelerate the discovery of novel, high-quality drug candidates."

John Baldoni, senior vice president at GSK, added: "We anticipate that their industry-leading approach will accelerate the discovery of new molecules against high-value GSK targets with speed and confidence, and without compromising quality."

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Today’s stories:

Concerns over Merck and Sigma-Aldrich merger

120 tons of counterfeit pesticides seized in Europe

Orthodontics companies in legal battle


More on this story

Big Pharma
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.

More on this story

Big Pharma
10 January 2020   Germany-based Bayer is collaborating with Exscientia, an artificial intelligence (AI)-driven drug discovery company, to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.